In Vivo Imaging of Mitochondria Structure and Function in Therapy Resistant Lung Tumors
难治性肺肿瘤线粒体结构和功能的体内成像
基本信息
- 批准号:10747207
- 负责人:
- 金额:$ 4.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAmericanAreaBiguanidesBioenergeticsBiological MarkersBiopsyCancer PatientCell LineCell RespirationClassificationClinicalComplexDataDependenceDiagnosisDiagnosticDiseaseDisease ResistanceDissectionElectron TransportEpidermal Growth Factor ReceptorExhibitsFunctional ImagingGene Expression ProfilingGenetically Engineered MouseGoalsHealthHumanImmuno-ChemotherapyImmunotherapyKRAS2 geneKnowledgeLung AdenocarcinomaLung NeoplasmsMaintenanceMalignant neoplasm of lungMeasuresMembrane PotentialsMetabolicMetabolic PathwayMetabolismMitochondriaMutationNon-Small-Cell Lung CarcinomaOncogenicOxidative PhosphorylationPatientsPhenotypePhosphorylation InhibitionPhysiologicalPositron-Emission TomographyRationalizationResearchResistanceResistance developmentSTK11 geneSiteSpirometryStructureSurvival RateTestingTherapeuticTimeTracerTyrosine Kinase InhibitorWorkadvanced diseasecancer therapycheckpoint therapydiagnostic strategydriver mutationfluorodeoxyglucoseimage guidedimaging probeimprovedin vivoin vivo imaginginhibitormetabolic profilemitochondrial membranemitochondrial metabolismmutantnano-stringneoplastic cellnovelnovel diagnosticsnovel strategiesnovel therapeutic interventionnovel therapeuticspatient derived xenograft modelstemsuperresolution microscopytargeted treatmenttherapy developmenttherapy resistanttreatment responsetumortumor initiationtumor metabolismuptake
项目摘要
Abstract
The overarching goal of this study is to identify effective metabolic based diagnostic and therapeutic strategies
to improve the overall survival of patients with Non-small cell lung cancer (NSCLC). We propose to investigate
the positron emission tomography (PET) tracer, 18F-BnTP as a novel metabolic diagnostic and to develop
metabolic based therapeutic strategies targeting oxidative mitochondrial metabolism in therapy resistant
KRAS/LKB1 and EGFR mutant lung tumors. NSCLC will claim the lives of ~130,000 in the US in 2021. Lung
tumors frequently possess a high mutational burden, often rendering single agent therapies targeting
oncogenic driver mutations unsuccessful. Furthermore, metabolically active subsets of lung adenocarcinomas
(LUADs) bearing mutations in KRAS and LKB1 or EGFR are frequently resistant to immunotherapy
approaches. However, regardless of the initials benefits from checkpoint inhibitors or targeted therapies, the
majority of patients will eventually develop resistance to therapy. We rationalize a different approach to
overcoming therapy resistance in NSCLC – namely the classification of tumors by their metabolic signature.
Here, tumors are grouped and targeted by their metabolic dependencies rather than solely by their genetic
alterations. NSCLC is a metabolically heterogeneous disease and tumors utilize both glycolytic and oxidative
mitochondrial metabolism to grow. The mitochondria are the site of cellular bioenergetics and oxidative
phosphorylation (OXPHOS) and are essential for lung tumor initiation and maintenance. Due to a lack of in
vivo imaging probes there is a gap in our knowledge at a physiological and mechanistic level of how
mitochondrial bioenergetics are regulated in NSCLC. To address this gap, we functionally imaged
mitochondrial activity in lung tumors utilizing the PET imaging tracer 18F-BnTP and demonstrate that it
functions an in vivo biomarker of mitochondrial membrane potential (ΔΨ) and oxidative phosphorylation
(OXPHOS) in lung tumors3. Importantly, by using 18F-BnTP PET imaging we are able to distinguish between
OXPHOS dependent and independent lung tumors. Therapeutically, we have demonstrated that 18F-BnTP
positive, OXPHOS-dependent LUADs are sensitive to mitochondrial complex I inhibitors. We hypothesize that
18F-BnTP PET imaging can be utilized to functionally profile mitochondrial bioenergetics and adaptive oxidative
metabolism in therapy-resistant lung tumors to guide treatment with OXPHOS inhibitors. In aim 1 we will
perform an in vivo dissection of mitochondrial bioenergetics in therapy-resistant LUADs. In aim 2 we will
perform a structural and functional in vivo analysis of adaptive oxidative metabolism in therapy-resistant
KRAS/LKB1 and EGFR mutant LUADs. In Aim 3 we will longitudinally profile oxidative metabolism in LUAD
patients with advanced disease. The proposed work has relevance to human health in which we propose that
18F-BnTP PET imaging guided targeting and oxidative metabolism represents a new therapeutic strategy to
overcome therapy resistance in patients with KRAS/LKB1 and EGFR mutant tumors.
摘要
这项研究的首要目标是确定有效的代谢为基础的诊断和治疗策略
提高非小细胞肺癌(NSCLC)患者的总生存率。我们建议调查
正电子发射断层扫描(PET)示踪剂18F-BnTP作为一种新型代谢诊断剂,
靶向治疗耐药的线粒体氧化代谢的基于代谢的治疗策略
KRAS/LKB 1和EGFR突变型肺肿瘤。2021年,NSCLC将在美国夺走约13万人的生命。肺
肿瘤通常具有高突变负荷,通常使得单药治疗靶向于
致癌驱动突变不成功。此外,肺腺癌的代谢活性亚群
携带KRAS和LKB 1或EGFR突变的LUAD通常对免疫治疗具有耐药性
接近。然而,无论最初从检查点抑制剂或靶向治疗中获益,
大多数患者最终会对治疗产生耐药性。我们用不同的方法
克服NSCLC中的治疗耐药性-即通过其代谢特征对肿瘤进行分类。
在这里,肿瘤是根据它们的代谢依赖性而不是仅仅根据它们的遗传特性来分组和靶向的。
改变。NSCLC是一种代谢异质性疾病,肿瘤利用糖酵解和氧化代谢
线粒体代谢来生长。线粒体是细胞生物能量学和氧化代谢的场所。
磷酸化(OXPHOS),并且对于肺肿瘤的起始和维持是必需的。由于缺乏在
体内成像探针在生理和机械水平上,我们的知识存在差距,
线粒体生物能量学在NSCLC中受到调节。为了解决这一差距,我们功能性地想象了
利用PET成像示踪剂18F-BnTP研究肺肿瘤中的线粒体活性,并证明
作为线粒体膜电位(Δ P)和氧化磷酸化的体内生物标志物,
(OXPHOS)在肺肿瘤中的作用3.重要的是,通过使用18F-BnTP PET成像,我们能够区分
OXPHOS依赖性和非依赖性肺肿瘤。在治疗上,我们已经证明18F-BnTP
阳性、OXPHOS依赖性LUAD对线粒体复合物I抑制剂敏感。我们假设
18F-BnTP PET成像可用于功能性地描绘线粒体生物能量学和适应性氧化代谢。
因此,本发明提供了在治疗抗性肺肿瘤中的代谢的新方法,以指导用OXPHOS抑制剂的治疗。在目标1中,
在治疗抗性LUAD中进行线粒体生物能量学的体内解剖。在目标2中,
在治疗抵抗性肿瘤中进行适应性氧化代谢的结构和功能体内分析,
KRAS/LKB 1和EGFR突变LUAD。在目标3中,我们将纵向描述LUAD中的氧化代谢
晚期疾病患者。拟议的工作与人类健康有关,我们建议,
18F-BnTP PET成像引导的靶向和氧化代谢代表了一种新的治疗策略,
克服KRAS/LKB 1和EGFR突变肿瘤患者的治疗耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David B Shackelford其他文献
David B Shackelford的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David B Shackelford', 18)}}的其他基金
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10866660 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10522994 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
治疗耐药性肺肿瘤线粒体结构和功能的体内成像
- 批准号:
10649562 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
(PQ5) LKB1 突变肺癌线粒体异质性成像
- 批准号:
9750637 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
9392856 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
9403002 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
(PQ5) LKB1 突变肺癌线粒体异质性成像
- 批准号:
10063382 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer
LKB1 突变肺癌线粒体异质性成像
- 批准号:
10585832 - 财政年份:2016
- 资助金额:
$ 4.07万 - 项目类别:
相似海外基金
African American (AA) Communities Speak: Partnering with AAs in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care
非裔美国人 (AA) 社区发言:与北部和南部的 AA 合作,培训姑息治疗临床医生,以解决人际和系统性种族主义并提供文化一致的护理
- 批准号:
10734272 - 财政年份:2023
- 资助金额:
$ 4.07万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10541028 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10684239 - 财政年份:2022
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10395616 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10786490 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10821849 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10384110 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10336591 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
社区学术伙伴关系解决非裔美国人社区内的 COVID-19 不平等问题
- 批准号:
10245326 - 财政年份:2021
- 资助金额:
$ 4.07万 - 项目类别:
Engaging scientists and communities to address the impacts of substance abuse on American Indian and Alaska Native children and families: The Native Children's Research Exchange Annual Meetings
让科学家和社区参与解决药物滥用对美洲印第安人和阿拉斯加原住民儿童和家庭的影响:原住民儿童研究交流年会
- 批准号:
10657317 - 财政年份:2020
- 资助金额:
$ 4.07万 - 项目类别:














{{item.name}}会员




